RHYTHM PHARMACEUTICALS, INC. Financing Cash Flow
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Financing Cash Flow of -$6.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.17M.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$5.40M, a 116.62% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$2.95M, a 107.69% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $189.30M, a 7496.35% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $217.96M, a 13.97% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $191.24M, a 157.16% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $74.37M, a 65.22% decline from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $213.83M, a 28.44% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$6.57M 10-Q · filed 2026-08-04 | -$9.51M derived: sum of 3 quarters · filed 2026-08-04 | $179.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$5.40M 10-Q · filed 2026-05-05 | -$8.35M derived: sum of 2 quarters · filed 2026-05-05 | $180.95M derived: sum of 3 quarters · filed 2026-05-05 | $180.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $186.35M derived: sum of 2 quarters · filed 2026-02-26 | $185.46M derived: sum of 3 quarters · filed 2026-08-04 | $217.96M 10-K · filed 2026-02-26 |
| 2025-09-30 | $189.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $188.41M derived: sum of 2 quarters · filed 2026-08-04 | $220.91M 10-Q · filed 2025-11-04 | $259.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$889.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $31.61M 10-Q · filed 2026-08-04 | $69.94M derived: sum of 3 quarters · filed 2026-08-04 | $72.43M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $32.50M 10-Q · filed 2026-05-05 | $70.83M derived: sum of 2 quarters · filed 2026-05-05 | $73.32M derived: sum of 3 quarters · filed 2026-05-05 | $219.50M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $38.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $40.82M derived: sum of 2 quarters · filed 2026-02-26 | $187.00M derived: sum of 3 quarters · filed 2026-02-26 | $191.24M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $148.67M derived: sum of 2 quarters · filed 2025-11-04 | $152.91M 10-Q · filed 2025-11-04 | $155.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $146.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $150.42M 10-Q · filed 2025-08-05 | $152.84M derived: sum of 3 quarters · filed 2026-02-26 | $225.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.24M 10-Q · filed 2025-05-07 | $6.67M derived: sum of 2 quarters · filed 2026-02-26 | $79.71M derived: sum of 3 quarters · filed 2026-02-26 | $78.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.47M derived: sum of 2 quarters · filed 2026-02-26 | $74.50M derived: sum of 3 quarters · filed 2026-02-26 | $74.37M 10-K · filed 2026-02-26 |
| 2023-09-30 | $73.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $72.08M derived: sum of 2 quarters · filed 2024-11-06 | $71.94M 10-Q · filed 2024-11-06 | $89.31M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$965.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.10M 10-Q · filed 2024-08-06 | $16.27M derived: sum of 3 quarters · filed 2025-02-28 | $174.83M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$133.00K 10-Q · filed 2024-05-07 | $17.23M derived: sum of 2 quarters · filed 2025-02-28 | $175.80M derived: sum of 3 quarters · filed 2025-02-28 | $213.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $17.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $175.93M derived: sum of 2 quarters · filed 2025-02-28 | $213.43M derived: sum of 3 quarters · filed 2025-02-28 | $213.83M 10-K · filed 2025-02-28 |
| 2022-09-30 | $158.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $196.06M derived: sum of 2 quarters · filed 2023-11-08 | $196.46M 10-Q · filed 2023-11-08 | $196.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $37.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $37.90M 10-Q · filed 2023-08-01 | $38.00M derived: sum of 3 quarters · filed 2024-02-29 | $38.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $399.00K 10-Q · filed 2023-05-02 | $499.00K derived: sum of 2 quarters · filed 2024-02-29 | $912.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $513.00K derived: sum of 2 quarters · filed 2024-02-29 | $896.00K derived: sum of 3 quarters · filed 2024-02-29 | $166.48M 10-K · filed 2024-02-29 |
| 2021-09-30 | $413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $796.00K derived: sum of 2 quarters · filed 2022-11-08 | $166.38M 10-Q · filed 2022-11-08 | $166.80M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $165.97M 10-Q · filed 2022-08-03 | $166.39M derived: sum of 3 quarters · filed 2023-03-01 | $167.09M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $165.59M 10-Q · filed 2022-05-03 | $166.00M derived: sum of 2 quarters · filed 2023-03-01 | $166.70M derived: sum of 3 quarters · filed 2023-03-01 | $166.89M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.12M derived: sum of 2 quarters · filed 2023-03-01 | $1.30M derived: sum of 3 quarters · filed 2023-03-01 | $2.01M 10-K · filed 2023-03-01 |
| 2020-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $882.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.59M 10-Q · filed 2021-11-02 | $163.55M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $890.00K 10-Q · filed 2021-08-03 | $162.85M derived: sum of 3 quarters · filed 2021-08-03 | $163.55M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $707.00K 10-Q · filed 2021-05-03 | $162.67M derived: sum of 2 quarters · filed 2021-05-03 | $163.37M derived: sum of 3 quarters · filed 2021-05-03 | $163.87M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $161.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $162.66M derived: sum of 2 quarters · filed 2021-03-01 | $163.16M derived: sum of 3 quarters · filed 2021-03-01 | $163.47M 10-K · filed 2021-03-01 |
| 2019-09-30 | $697.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $1.20M derived: sum of 2 quarters · filed 2020-11-02 | $1.51M 10-Q · filed 2020-11-02 | $1.66M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $814.00K 10-Q · filed 2020-08-03 | $967.00K derived: sum of 3 quarters · filed 2021-03-01 | $2.14M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $316.00K 10-Q · filed 2020-05-04 | $469.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.64M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.33M derived: sum of 2 quarters · filed 2021-03-01 | $164.69M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $164.53M 10-Q · filed 2019-11-01 | ||
| 2018-06-30 | $163.36M 10-Q · filed 2019-07-29 | |||
| 2017-12-31 | $125.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $146.82M derived: sum of 2 quarters · filed 2020-03-02 | $146.82M derived: sum of 3 quarters · filed 2020-03-02 | $167.20M 10-K · filed 2020-03-02 |
| 2017-09-30 | $21.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $21.16M derived: sum of 2 quarters · filed 2018-11-09 | $41.54M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $20.38M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $20.38M 10-Q · filed 2018-05-14 | |||
| 2015-12-31 | $41.71M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |